Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Global Glioblastoma Multiforme Market Portaiture
2.2 Global Glioblastoma Multiforme Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Glioblastoma Multiforme Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3 Glioblastoma Multiforme Market: Market Dynamics and Outlook
3.1 Glioblastoma Multiforme Market Overview
3.2 Glioblastoma Multiforme Disease Overview and Treatments
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Glioblastoma Multiforme Market, 2015 (Value %)
Chapter 4 GlobalGlioblastoma Multiforme Market, By Type of Drug
4.1 Preface
4.2 Bevacizumab
4.3 Temozolomide
4.4 Carmustine
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 TRC-105
4.6.1.2 VB-111
4.6.1.3 TOCA 511
4.6.1.4 DCVax-Brain
4.6.1.5 Rindopepimut (CDX-110)
4.6.1.6 ICT-107
4.6.1.7 Others
4.6.2 Tabular Representation of Phase II and I Drugs
Chapter 5 Global Glioblastoma Multiforme Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa
Chapter 6 Company Profiles
6.1 AbbVie, Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Activartis GmbH
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Agenus Inc.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Arog Pharmaceuticals, Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Bristol-Myers Squibb Company
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Cavion LLC
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Celldex Therapeutics, Inc .
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Cortice Biosciences Inc.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Eisai Co., Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 F. Hoffmann-La Roche Ltd.
6.11.1 Business Description
6.11.2 Financial Health and Budget Allocation
6.11.3 Product Portfolio
6.11.4 News Coverage
6.12 Exelixis Inc.
6.12.1 Business Description
6.12.2 Financial Health and Budget Allocation
6.12.3 Product Portfolio
6.12.4 News Coverage
6.13 Peregrine Pharmaceuticals, Inc.
6.12.1 Business Description
6.12.2 Financial Health and Budget Allocation
6.12.3 Product Portfolio
6.12.4 News Coverage
List of Figures
FIG. 1 Global Glioblastoma Multiforme Market, by Type of Drugs, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Glioblastoma Multiforme Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Glioblastoma Multiforme Market, 2015
FIG. 4 Market Share Analysis: Global Glioblastoma Multiforme Market, 2015 (Value %)
FIG. 5 Global Bevacizumab Market, 2013 – 2022 (USD Mn)
FIG. 6 Global Temozolomide Market, 20137– 2022 (USD Mn)
FIG. 7 Global Carmustine Market, 2013 –2022 (USD Mn)
FIG. 8 Pipeline Analysis: Global TRC-105 Market, Upto 2022 (USD Mn)
FIG. 9 Pipeline Analysis: Global VB-111 Market, Upto 2022 (USD Mn)
FIG. 10 Pipeline Analysis: Global TOCA 511 Market, Upto 2022 (USD Mn)
FIG. 11 Pipeline Analysis: Global DCVax-Brain Market , Upto 2022 (USD Mn)
FIG. 12 Pipeline Analysis: Global Rindopepimut (CDX-110) Market, Upto 2022 (USD Mn)
FIG. 13 Pipeline Analysis: Global ICT-107 Market, Upto 2022 (USD Mn)
FIG. 14 Pipeline Analysis: Global Trivax (AV00113) Market, Upto 2022 (USD Mn)
FIG. 15 U.S.Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 16 Canada Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 17 U.K Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 18 Germany Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 19 Rest of Europe Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 20 China Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 21 Japan Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 22 Rest of Asia Pacific Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 23 Brazil Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 24 Mexico Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 25 Rest of the Latin America Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 26 Middle East and Africa Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
List of Tables
TABLE 1 Global Glioblastoma Multiforme Market, by Type of Drugs, 2013 – 2022 (USD Mn)
TABLE 2 Global Glioblastoma Multiforme Market, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia – Pacific Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Latin America Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)